ArticleFrontiers in oncology2026
Case Report: Rare gastric and bone metastases after early endocrine therapy discontinuation in hormone receptor-positive breast cancer: lessons and therapeutic insights.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer with gastric metastasis is extremely rare. Non-persistence with adjuvant endocrine therapy is associated with increased recurrence/metastasis risk in hormone receptor-positive (HR+) breast cancer. A 33-year-old female was initially diagnosed with left breast cancer in July 2011, undergoing modified radical mastectomy, adjuvant chemotherapy, radiotherapy, and endocrine therapy (discontinued voluntarily after 1 year). In February 2025, she presented with low back pain and epigastric discomfort; examinations confirmed gastric and multiple bone metastases (ER+,PR+,HER2-). She received first-line endocrine therapy (letrozole+ribociclib+goserelin) combined with denosumab. Re-examination in September 2025 showed normal CEA, significantly decreased CA153, and no disease progression per RECIST 1.1. This case suggests that early endocrine therapy discontinuation may potentially contribute to late recurrence/metastasis. Breast cancer gastric metastasis diagnosis relies on medical history, gastroscopy, and immunohistochemistry (GATA3+, CK7+, CK20-). The combination regimen yielded favorable efficacy, providing clinical reference for similar rare cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.